

#150

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Tuesday, September 30, 2025 2:02:40 PM
Last Modified: Tuesday, September 30, 2025 2:07:33 PM
Time Spent: 00:04:53
IP Address: 184.105.203.130

Page 2: Part 1

Q1

Title of activity

aeroallergen SLIT: practical aspects and current evidence

Q2

Date of activity

oct 18, 2025

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Combination - Community and Academic

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas) **stallergenes, bausch**

Description of relationship(s) **speaker**

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

sanofi

Description of relationship(s)

ad board

Q8

Respondent skipped this question

Funded grants or clinical trials

Q9

Respondent skipped this question

Patents on a drug, product or device

Q10

Respondent skipped this question

All other investments or relationships that could be seen
by a reasonable, well-informed participant as having the
potential to influence the content of the educational activity

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note:
Only generic names should be used whenever possible. If
trade names are used, they should be accompanied by the
generic name.

Q12

No

I intend to make therapeutic recommendations for
medications that have not received regulatory approval
(i.e. "off-label" use of medication). Note: You must declare
all off-label use to the audience during your presentation.

Q13

No

If you answered "Yes" to the previous question, are the
medications recommended manufactured by companies
you have received funding from?

Q14

Yes

I acknowledge that the National Standard requires that any
description of therapeutic options utilize generic names (or
both generic and trade names) and not reflect exclusivity
and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15 **Yes**

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

godfrey

Q17

Last Name:

Iam

Q18 **He/Him**

Gender Pronouns - How would you like us to address you?

Q19	I confirm that the above information is accurate and complete.
Please review and check the items below.	,
	I understand that this information may be publicly available
